{
    "Trade/Device Name(s)": [
        "Hightop\u00ae Home Use Fentanyl/Norfentanyl Urine Rapid Test Panel",
        "Hightop\u00ae Fentanyl/Norfentanyl Urine Rapid Test Panel"
    ],
    "Submitter Information": "Qingdao HIGHTOP Biotech Co., Ltd.",
    "510(k) Number": "K241969",
    "Predicate Device Reference 510(k) Number(s)": [
        "K233417"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NGL"
    ],
    "Summary Letter Date": "July 3, 2024",
    "Summary Letter Received Date": "July 5, 2024",
    "Submission Date": "July 3, 2024",
    "Regulation Number(s)": [
        "21 CFR 862.3650"
    ],
    "Regulation Name(s)": [
        "Opiate Test System"
    ],
    "Analyte Class(es)": [
        "toxicology"
    ],
    "Analyte(s)": [
        "Fentanyl",
        "Norfentanyl"
    ],
    "Specimen Type(s)": [
        "Urine"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [],
    "Method(s)/Technology(ies)": [
        "Competitive binding immunochromatographic assay",
        "Lateral flow"
    ],
    "Methodologies": [
        "Immunochemistry"
    ],
    "Submission Type(s)": [
        "Panel",
        "Cassette"
    ],
    "Document Summary": "FDA 510(k) summary for Hightop Home Use and Professional Fentanyl/Norfentanyl Urine Rapid Test Panel for qualitative detection of fentanyl and norfentanyl in human urine",
    "Indications for Use Summary": "Qualitative detection of fentanyl and norfentanyl in human urine at defined cut-off concentrations using an OTC rapid lateral flow immunochromatographic panel; provides preliminary results requiring confirmation by alternative chemical methods such as GC/MS or LC/MS.",
    "fda_folder": "Toxicology"
}